High-Fiber diet may cut Early-Onset bowel cancer risk
NCT ID NCT07279454
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a modified high-fiber version of the UK's EatWell diet can improve health markers linked to early-onset colorectal cancer. Two hundred adults in the UK will follow either the standard EatWell diet (30g fiber/day) or a modified version (40g fiber/day) for 12 weeks. Researchers will measure changes in stool, blood, urine, and saliva to see if extra fiber makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Modified EatWell diet (high-fiber, 40g/day)
- What this could lead to
- If it works, this could point toward a dietary approach to lower the risk of early-onset bowel cancer.
- What could go wrong
- This is a small, early-stage trial looking at biological markers, not cancer itself. The diet may be hard to follow long-term, and results may not translate to actual cancer prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion * If female, not pregnant, lactating, or planning a pregnancy within the next 4 months. * Living in the United Kingdom. Exclusion * Dietary fibre intake \<16 g/day or \>30 g/day. * Unwilling to comply with the intervention (wholegrains, beans and pulses, and nuts and seeds). * Are diagnosed with the following food allergies: gluten, peanuts, or nuts. * Are living or have a past medical history of an eating disorder. * Alcohol Use Disorders Identification Test - Consumption score \> 10 points. * Have lost significant weight (\>10% of original bodyweight) over the past 3 months. * Use of any of the following drugs within the last month: (i) antifungals, antivirals, or antiparasitic medications (ii) methotrexate or immunosuppressive agents. * Use of systemic antibiotics within the last 3 months. * Use of commercial probiotics, prebiotics, laxatives, or other gut health supplements within the last month. * Using Glucagon-Like Peptide-1 Receptor Agonists. * Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. * Undergoing dietetic care for chronic conditions. * History of cancer, except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision. * Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired), including human immunodeficiency virus infection. * Major surgery of the GI tract, except for cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time. * Any other condition declared by the participant deemed by the medical supervisor to affect the normal conduct of the study and analysis of results. * History of active, uncontrolled gastrointestinal disorders or diseases, including: (i) Coeliac disease (ii) inflammatory bowel disease, including ulcerative colitis, Crohn's disease, or indeterminate colitis (iii) persistent, infectious gastroenteritis, colitis or gastritis (iv) persistent or chronic diarrhoea of unknown aetiology (v) chronic constipation (vi) Irritable Bowel Syndrome (vii) Clostridium difficile infection (recurrent) (viii) Helicobacter pylori infection (untreated). * Any other condition declared by the participant deemed by the medical supervisor to affect the normal conduct of the study and analysis of results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Microbiome related mechanisms linked to early onset colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Twin Research and Genetics
London, SE1 7EH, United Kingdom